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Progression criteria in trials with an internal
pilot: an audit of publicly funded
randomised controlled trials
Esther Herbert* , Steven A. Julious and Steve Goodacre
Abstract
Background: With millions of pounds spent annually on medical research in the UK, it is important that studies are
spending funds wisely. Internal pilots offer the chance to stop a trial early if it becomes apparent that the study will
not be able to recruit enough patients to show whether an intervention is clinically effective. This study aims to
assess the use of internal pilots in individually randomised controlled trials funded by the Health Technology
Assessment (HTA) programme and to summarise the progression criteria chosen in these trials.
Methods: Studies were identified from reports of the HTA committees’ funding decisions from 2012 to 2016. In
total, 242 trials were identified of which 134 were eligible to be included in the audit. Protocols for the eligible
studies were located on the NIHR Journals website, and if protocols were not available online then study managers
were contacted to provide information.
Results: Over two-thirds (72.4%) of studies said in their protocol that they would include an internal pilot phase for
their study and 37.8% of studies without an internal pilot had done an external pilot study to assess the feasibility
of the full study. A typical study with an internal pilot has a target sample size of 510 over 24 months and aims to
recruit one-fifth of their total target sample size within the first one-third of their recruitment time.
There has been an increase in studies adopting a three-tiered structure for their progression rules in recent years,
with 61.5% (16/26) of studies using the system in 2016 compared to just 11.8% (2/17) in 2015. There was also a
rise in the number of studies giving a target recruitment rate in their progression criteria: 42.3% (11/26) in 2016
compared to 35.3% (6/17) in 2015.
Conclusions: Progression criteria for an internal pilot are usually well specified but targets vary widely. For the
actual criteria, red/amber/green systems have increased in popularity in recent years. Trials should justify the targets
they have set, especially where targets are low.
Keywords: Internal pilot, Audit, Feasibility, Recruitment
Background
In the financial year 2015/16, the National Institute for
Health Research (NIHR) spent £247.9 million on their
research programmes and almost a third of this was
spent on their Health Technology Assessment (HTA)
programme [1]. With such large amounts of public
money being spent on health research, it is important
that the funds are used wisely and that money is not
wasted on trials which are not likely to succeed.
An internal pilot is a phase in a trial after which progress
is assessed against pre-specified targets/criteria [2, 3]. They
are an opportunity to stop trials which are not likely to
reach their recruitment, retention or site set-up targets
(among others). Unlike an external pilot, data collected dur-
ing the internal pilot phase contribute towards the final
analyses of a trial. This makes internal pilots potentially
more cost-effective than running an external pilot followed
by a full trial. Including an internal pilot in a study allows
funders to take on more risky trials, such as trials where re-
cruitment to time and target is uncertain due to a lack of
previous research in the clinical area or a trial population
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with a rare disease; if the internal pilot shows that the trial
is not feasible, it can be stopped short to save resources.
Internal pilots give trialists the opportunity to investi-
gate other elements of the trial such as a sample size re-
estimation [4], assessments of futility and adherence to
intervention. However, for the purpose of this research
the focus is on internal pilots as a means to evaluate or
monitor study recruitment, and other progression cri-
teria specified by audited trials were ignored.
Trials fail for a variety of reasons including: not
recruiting the target sample size; higher levels of drop-
out or non-compliance than planned for; or flaws in the
trial design such as an impractical method of randomisa-
tion. Recruitment is a key area of interest since failing to
hit a recruitment target could leave a trial with less
power to detect a clinically meaningful and statistically
significant result. According to an audit of randomised
controlled trials (RCTs) funded by the NIHR HTA
programme, only 56% (85/151) of studies achieved their
target sample size [5].
This article aims to provide a summary of the continu-
ation criteria used in trials with internal pilots funded by
the NIHR HTA programme as well specific examples of
good progression criteria.
Methods
Identifying trials
Funding outcomes from the HTA’s Clinical Evaluation
and Trials (CET) and Commissioning Committees [6]
were reviewed for meetings between February 2012 and
November 2016 inclusive. These committees meet regu-
larly to discuss both researcher-led proposals and re-
sponses to the HTA’s commissioned calls. The
committees then make recommendations to the HTA
Prioritisation Group. Trials funded by the HTA
programme were chosen because it is the largest re-
search programme within the NIHR; HTA funding made
up 30% of all research programme funding in 2015/16
[1]. HTA-funded trials were also chosen because of the
level of quality planning required for funding.
Funded trials were then identified on the NIHR Journals
website [7], where details of funded projects are given and
study protocols are uploaded. The protocols listed were
used to determine whether the study was suitable for the
audit. Studies were included in the audit if they were indi-
vidual randomised controlled trials with a listed protocol.
Analyses
Trials were categorised by whether they had an internal
pilot, external pilot, neither or both and the proportions
of trials in each were compared by year of trial funding
approval. The year of funding approval was chosen in-
stead of the year of trial start because it was believed to
form a more accurate representation of the trends in
pilot inclusion. Trials do not start immediately after
funding approval and the period between funding deci-
sion and starting can vary a lot; this means that the start
date for a trial may not be a good indicator of trends in
trials practice since the protocol trial design will have
been decided a varying time before.
In the paper by Avery et al. [8], recommendations
were made for developing progression criteria for in-
ternal pilots. The trials in our audit were analysed to see
whether they followed two of the top tips from the
article:
Question Recommendation
• Were the criteria given as a
stop/go decision (e.g. continuation
based on meeting a set target) or
as a more complex red/amber/
green decision, where studies
falling into the amber section
would require more discussion as
to whether they would continue?
• Avery et al. [8] recommended
using the red/amber/green
system.
• Were criteria based on
recruitment targets given as a
target number of patients recruited
or as a target recruitment rate?
• Rates per centre per unit time
were recommended since they
can then be used to extrapolate
the predicted full recruitment
length and are not as susceptible
to sites opening late.
The red/amber/green system for progression criteria
gives a three-tiered approach as illustrated in Fig. 1.
For example, the green criteria might be that trials will
be allowed to continue if they recruit at 100% of their
pre-specified target for that period; the amber criteria
could be that if the trial recruits at less than 100% of
their target but better than 60%, then things will be
looked into; and the red criteria would then be that if
Fig. 1 Illustration of the red/amber/green system of criteria
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recruitment fell to less than 60% of the target the trial
would end.
Results from these questions were also compared by
year of funding approval to see whether there has been a
change in the types of criteria used across the years.
A further question we wished to investigate was the
duration of internal pilots as a proportion of the planned
full trial. In order to assess this, we looked at the length
of the pilot phase in terms of months of recruitment and
recruitment target. Recruitment targets for internal
pilots were not always given, for example when
progression targets were given as recruitment rates. In
these cases, the target number of patients recruited for
the pilot was extrapolated where possible.
All analyses were performed in R (version 3.5.1) [9].
Results
Through documentation of funding decisions found on
the NIHR webpage [6], 242 studies were identified. Of
these, 134 (55.4%) were included in the audit. Reasons
for exclusion included the following:
 The study was an external pilot/feasibility study.
 The protocol was missing.
 The study was a systematic review.
Efforts were made to contact study managers for
studies where the protocol was missing from the NIHR
Journals library, but it was not always possible to obtain
the information needed. The CONSORT-style diagram
in Fig. 2 shows the flow of studies through the audit,
including reasons for exclusion from the study.
On average, 26.8 (12.19) trials were approved each year
and met our inclusion criteria. However, only funding
decisions made in February were available for 2012. This
means it is only sensible to look at data from 2013 to 2016
when assessing trends across the years but the data from
2012 have been included for completeness. For all other
years, data were available for at least 3 months, with data
for 1 month more available in 2013 which explains the
slight increase in studies from that year.
Out of the 134 studies included in the audit, 72.4% (97/
134) said that they would include an internal pilot in their
protocol. Of those that did not include an internal pilot,
37.8% (14/37) had done an external pilot prior to their
study approval. This means that 82.8% (111/134) of studies
audited included some form of pilot/feasibility work.
The Big CACTUS study [10] approved in 2013 included
an internal pilot phase having already completed an
external pilot [11]. This was due to significant changes
made after the external pilot, including the addition of
another arm to the trial.
Table 1 presents the properties of the studies included
in the audit, broken down by whether an internal pilot
was included. There appears to be no difference between
the types of studies with or without an internal pilot.
Figure 3 shows the breakdown of how many studies
included pilots (either internal or external) by year of
funding approval. The proportion of studies including
an internal pilot has increased over the years but 10.0%
Fig. 2 Flow of studies through the audit
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Table 1 Characteristics of the trials audited (n = 134) stratified by the presence of an internal pilot
Internal pilot No internal pilot Total
Disease area Cancer 14 (82.4%) 3 (17.6%) 17
Circulatory system 6 (60.0%) 4 (40.0%) 10
Digestive system 1 (50.0%) 1 (50.0%) 2
Ear, nose and throat 1 (50.0%) 1 (50.0%) 2
Eye diseases 3 (75.0%) 1 (25.0%) 4
Infections and infestations 5 (100.0%) 0 (0.0%) 5
Injury, occupational diseases, poisoning 5 (71.4%) 2 (28.6%) 7
Mental and behavioural disorders 14 (60.9%) 9 (39.1%) 23
Musculoskeletal diseases 11 (84.6%) 2 (15.4%) 13
Neonatal diseases 2 (100.0%) 0 (0.0%) 2
Nervous system diseases 6 (66.7%) 3 (33.3%) 9
Pregnancy and childbirth 9 (60.0%) 6 (40.0%) 15
Respiratory 4 (80.0%) 1 (20.0%) 5
Skin and connective tissue diseases 3 (75.0%) 1 (25.0%) 4
Urological and genital diseases 6 (66.7%) 3 (33.3%) 9
Othera 7 (100.0%) 0 (0.0%) 7
Power 80% 12 (66.7%) 6 (33.3%) 18
85% 1 (100.0%) 0 (0.0%) 1
90% 75 (73.5%) 27 (26.5%) 102
95% 1 (50.0%) 1 (50.0%) 2
Other 8 (72.7%) 3 (27.3%) 11
Year of funding decision 2012 2 (28.6%) 5 (71.4%) 7
2013 29 (72.5%) 11 (27.5%) 40
2014 20 (76.9%) 6 (23.1%) 26
2015 20 (64.5%) 11 (35.5%) 31
2016 26 (86.7%) 4 (13.3%) 30
aGenetic diseases; nutritional, metabolic, endocrine; oral health; signs and symptoms; surgery; and not applicable
Fig. 3 Number of studies with an internal pilot, an external pilot or no pilot, broken down by year
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(3/30) of RCTs approved in 2016 still did not have any
pilot work either internally or externally.
Of the 97 studies that indicated in their protocol that
they would include an internal pilot, 89.7% (87/97) gave
criteria for progression from the pilot phase to the full
trial. Table 2 presents the proportions of studies using
stop/go or red/amber/green systems and whether the
number or the rate was given for targets involving
recruitment. The most popular format for criteria was a
stop/go system with a recruitment target given in terms
of the number of patients to be recruited; this was seen
in 44.8% (39/87) of the studies that gave criteria.
In 2016 there was an increase in studies adopting
the red/amber/green structure for their progression
rules, with 61.5% (16/26) of studies using the system
compared to just 11.8% (2/17) in 2015. There was
also a rise in the number of studies giving a target
recruitment rate in their progression criteria: 42.3%
(11/26) in 2016 compared to 35.3% (6/17) in 2015.
Figures 4 and 5 show the change in the proportion
of studies using different types of criteria across the
years. Proportions were calculated excluding trials
with an internal pilot but no progression criteria
stated in the trial protocol.
Table 3 presents details of what proportion of a
trial is used for the internal pilot phase. The average
proportion of recruitment months used in the pilot is
33.5% (SD 12.6%). However, the average proportion of
the sample size aimed to be recruited in the internal
pilot was 18.5% (SD 10.4%).
A typical study with an internal pilot having a target
sample size of 510 over 24 months aims to recruit one-
fifth of their total target sample size within the first one-
third of their recruitment time; this ratio of proportion
of sample size to proportion of recruitment length (3:5)
allows for slow initial recruitment during set-up of
centres. We are not looking here at a within-site lag to
recruitment (i.e. a slow start caused by staff familiarising
themselves with the protocol) but, rather, a lag caused
by the process of setting up multiple centres whilst
recruitment is ongoing. In this sense, we would expect
larger multi-centre studies to have a longer lag phase
across the whole study resulting in a lower, more
generous ratio of the proportion of the sample size to
proportion of recruitment length and we would expect a
more ambitious ratio, closer to 1, for studies with only a
few sites which could all be set-up and recruiting close
to the start of recruitment.
However, there appears to be little association between
this ratio and the total number of centres involved in a
study. Figure 6 suggests that studies with few centres (< 7)
have a fractionally more ambitious ratio than studies with
more centres but there is no clear association. This
suggests that studies with fewer centres are not being
ambitious enough with their recruitment target for their
internal pilot, although most studies do not aim to open
all of their sites during the internal pilot phase and we
cannot exclude the possibility that overall site set-up has
been allowed for in the recruitment target.
However, the target proportion of patients recruited
for the internal pilot did vary depending on the relative
length of the internal pilot compared to the full trial.
Figure 7 shows that, as expected, the larger the
proportion of the recruitment period included in the
pilot phase, the larger the target sample size for the
internal pilot as a proportion of the main target sample
size. For example, studies whose internal pilot took up
less than 25% of their recruitment months aimed to
recruit 9.8% of their target sample size in this time,
whereas studies whose internal pilot took up between
33.3% and 41% of their recruitment months aimed to
recruit 15.3% of their target sample size.
Exemplars
Coming up with progression criteria can often feel
like an abstract concept and pre-specifying desired
recruitment rates along with thresholds at which
changes should be investigated or the trial should be
stopped is difficult. It is helpful to look at examples
to get a picture of what clear criteria look like. The
following trials have given well thought out
progression criteria with a red/amber/green structure
and criteria based on rates.
EASI-SWITCH trial [12]
Criteria
Recruitment rate (the expected recruitment rate is 1.7
patients per site per month with a 50% reduction for
the first three months of site opening):
Progression without major modification if at
least 75% of target reached, with analysis and
resolution of any identified barriers to successful
recruitment.
Progression with addition of further trial sites if
between 50 and 75% of target reached.
Table 2 Criteria specifications for all 97 studies with an internal
pilot included in the audit
Number/rate Type of criteria
Red/amber/green Stop/go Missing
Number 18 (18.6%) 39 (40.2%) 0 (0.0%)
Number and rate 1 (1.0%) 4 (4.1%) 0 (0.0%)
Rate 10 (10.3%) 15 (15.5%) 0 (0.0%)
Missing 0 (0.0%) 0 (0.0%) 10 (10.3%)
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Progression unlikely if less than 50% of target
reached—this equates to, on average, 4 patients per
site over the 12 month pilot period. This would be
subject to detailed review of project viability by
the Trial Steering Committee and HTA team. ([12],
p. 23)
This criteria specification clearly states their three-tiered
system which gives next steps should the trial fall into
each category and allows for slower recruitment as trials
open. The only potential problem is that, with the “green”
target set at 75%, the trial could continue without
modification towards an underpowered total sample. A
“green” target of 100%, with proportionate responses to
recruitment in the 75–10%% range, would address this
concern.
Prepare for Kidney Care trial [13]
Criteria
This trial presented their progression criteria in a helpful
table (see Table 4). The protocol for the Prepare for
Kidney Care trial says that if all green targets are
achieved then the full trial would most likely go ahead,
whereas predominantly red targets would probably
illustrate that the full trial would not be feasible. The
simple table clearly displays all progression criteria. In
particular, the criteria for recruitment are given as rates
to allow assessment of whether it is the rate or site set-
up or the recruitment rate per site that is failing to meet
the target. Again, it would need to be clarified that an
overall rate between 85 and 100% would involve some
sort of remedial action to protect against an under-
powered trial.
Fig. 4 Trend in whether the recruitment rate or the number recruited was used in criteria for internal pilots
Fig. 5 Trend in whether a red/amber/green system or a stop/go system was used for progression criteria
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Table 3 Recruitment properties of the studies audited, stratified by presence of an internal pilot
Internal pilot
(N = 97)
No internal pilot
(N = 37)
Total
(N = 134)
Total target sample size n 97 36 133
Mean (SD) 945.1 (1400.0) 1171.8 (1460.3) 1006.5 (1414.6)
Median (IQR) 510.0 (350.0,
900.0)
625.0 (395.0, 1,
349.2)
533.0 (360.0, 1,
044.0)
Minimum,
maximum
120, 9920 100, 8000 100, 9920
Recruitment target for internal pilot n 69 – 69
Mean (SD) 135.2 (156.8) – 135.2 (156.8)
Median (IQR) 100.0 (48.0, 162.0) – 100.0 (48.0, 162.0)
Minimum,
maximum
20, 1165 – 20, 1165
Proportion of sample size aimed to be recruited in internal pilot
(%)
n 69 – 69
Mean (SD) 18.5 (10.4) – 18.5 (10.4)
Median (IQR) 15.8 (10.2, 25.0) – 15.8 (10.2, 25.0)
Minimum,
maximum
2.3, 50 – 2.3, 50
Length of recruitment for full study (months) n 96 35 131
Mean (SD) 28.6 (10.9) 22.3 (9.1) 26.9 (10.8)
Median (IQR) 24.0 (20.8, 36.0) 20.0 (16.5, 30.0) 24.0 (18.0, 36.0)
Minimum,
maximum
11, 60 5, 45 5, 60
Length of recruitment for internal pilot (months) n 96 – 96
Mean (SD) 9.4 (5.1) – 9.4 (5.1)
Median (IQR) 8.5 (6.0, 12.0) – 8.5 (6.0, 12.0)
Minimum,
maximum
3, 30 – 3, 30
Proportion of recruitment length used in internal pilot (%) n 95 – 95
Mean (SD) 33.5 (12.6) – 33.5 (12.6)
Median (IQR) 33.3 (25.0, 40.8) – 33.3 (25.0, 40.8)
Minimum,
maximum
9.4, 68.8 – 9.4, 68.8
Number of centres involved in full study n 91 30 121
Mean (SD) 20.9 (22.1) 19.9 (17.1) 20.6 (20.9)
Median (IQR) 14.0 (7.5, 25.0) 15.5 (6.0, 29.0) 14.0 (7.0, 26.0)
Minimum,
maximum
1, 120 3, 70 1, 120
Number of centres involved in internal pilot n 88 – 88
Mean (SD) 9.4 (11.6) – 9.4 (11.6)
Median (IQR) 6.0 (4.0, 12.0) – 6.0 (4.0, 12.0)
Minimum,
maximum
1, 100 – 1, 100
Proportion of centres used in internal pilot (%) n 86 – 86
Mean (SD) 56.8 (31.3) – 56.8 (31.3)
Median (IQR) 49.0 (33.3, 100.0) – 49.0 (33.3, 100.0)
Minimum,
maximum
9.5, 100 – 9.5, 100
IQR interquartile range, SD standard deviation
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Discussion
Although they are the gold standard, clinical trials are an
expensive way of making an assessment for a new health
technology. To ensure optimal value for the research
funding—particularly for public funding—it is good
practice to have some formal decision criteria within a
trial to help the trialists and the funding body decide
whether it is feasible to continue with the trial.
Stop/go criteria within the trial are a method to help to
determine whether the trial is feasible for the budget set
where the criteria are set before the commencement of
the trial and are agreed with the funder. In recent years, a
traffic light system has been proposed where decisions are
set out such that red equates to stop, green to go and
amber to further action. This format of setting out
progression criteria has increased in popularity amongst
HTA-funded trials in the past few years and has the
advantage of providing an amber zone that can be used to
prompt remedial action rather than close down.
Choice of timing and targets for an internal pilot are
important. Regardless of the timing, specifying the
decision criteria as an average recruitment rate per month
per site allows for a check as to whether the pilot has
shown that the trial is feasible. If you multiply the
recruitment rate per month per site achieved in the pilot
by the number of sites and months across the whole trial
you should get the total sample size.
Our investigation has looked only at studies funded by the
NIHR HTA programme, as such this work has limited
generalisability but will hopefully be of use to those
Fig. 6 Boxplots showing the ratio of pilot recruitment target to internal pilot length stratified by the quartiles of the total number of centres in
the trials
Fig. 7 Boxplots showing the proportion of patients aimed to be recruited stratified by the proportion of the trial taken up by the internal pilot
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preparing grant applications for this and other publicly
funded programmes where funding is limited and there is
pressure to obtain results from resources used for research.
It would be interesting for further work to explore whether
similar trends in internal pilots have been seen across trials
funded by other streams of the NIHR and other funding
bodies.
A limitation of this work is that results presented cannot,
in general, be applied to cluster RCTs because they were
excluded from the audit due to complexities surrounding
recruitment strategies. For example, in some cluster RCTs
individuals are not directly recruited; in the PLEASANT
trial [14], GP practices were recruited and randomised and
routine data were collected through the Clinical Practice
Research Datalink (CPRD). Further work to investigate
progression criteria for internal pilots within a cluster RCT
would have to consider the different models of recruitment
used.
Conclusions
Progression criteria for an internal pilot are usually
specified but targets vary widely. Red/amber/green systems
have become more popular in recent years for specifying
targets for progression. If these criteria are used with a
target for the average rate per site per months in the pilot
phase, this should produce the total sample size when
extrapolated across the sites and duration of the full trial.
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Table 4 Progression criteria table from the Prepare for Kidney Care trial protocol ([13], p. 54)
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Amber 60–84 10–13 sites 0.9–1.2 patients/month
Red < 60 9 sites or fewer 0.8 patients/month or fewer
Adapted from [13]
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